Navigating GLP-1 Switches: A Guide for Primary Care

https://www.medscape.com/viewarticle/navigating-glp-1-switches-guide-primary-care-2026a100107z?ecd=WNL_trdalrt_pos1_ous_260930_etid8746389&uac=148436CN&impID=8746389 As GLP-1 receptor agonists and dual incretin agents become more common in treating obesity and type 2 diabetes, primary care providers are handling more medication switches. The reason may be insurance coverage, ongoing gastrointestinal side effects, inadequate response, or the need for better blood sugar control or weight support. Whatever the driver, switching is not simply trading one prescription for another. It requires planning around half-lives, dose history, side effects, and the risk for blood sugar swings.